source
- Viatris to acquire Pacira BioSciences for $1.65 billion to expand non‑opioid pain portfolioViatris announced a $1.65 billion acquisition of Pacira BioSciences, aiming to broaden its non‑opioid pain‑relief offerings. The deal includes Pacira's marketed products Exparel and Zilretta, which…
- Hospitals file second lawsuit to block Trump admin's 340B rebate pilotThe American Hospital Association (AHA) has filed another lawsuit against the federal government, challenging a new version of the 340B drug discount program proposed by the Trump administration.…